Biogen (BIIB)
Develops neurological medicines spanning MS, rare disease, Alzheimer’s, and complement-mediated conditions.
$221.76
vs last close+2.69 (+1.23%)
Something off on this page? Send us feedback.
Next report
Oct 28, 26
in 36 days
EPS estimate
$2.03
Revenue estimate
$2.64B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$3.44$3.02$5.47$4.81$1.99$3.57$3.60Pending
Estimate$3.43$2.90$3.90$3.88$1.63$3.05$2.94$2.03
Surprise+0.3%+4.1%+40.3%+24.0%+22.1%+17.0%+22.4%—
RevenueReportedEstimate
Feb '25May '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$2.45B$2.43B$2.65B$2.45B$2.28B$2.48B$2.74BPending
Estimate$2.41B$2.23B$2.33B$2.34B$2.20B$2.29B$2.46B$2.64B
Surprise+1.9%+8.8%+13.6%+4.9%+3.5%+8.4%+11.2%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $5.81 | — | — |
| Sep 2028 | $5.40 | — | — |
| Jun 2028 | $5.96 | — | — |
| Mar 2028 | $5.86 | — | — |
| Dec 2027 | $4.48 | — | — |
| Sep 2027 | $4.27 | — | — |
| Jun 2027 | $4.31 | — | — |
| Mar 2027 | $3.69 | — | — |
| Dec 2026 | $3.27 | — | — |
| Oct 2026 | $2.03 | — | — |
| Jul 2026 | $2.94 | $3.60 | +22.4% |
| Apr 2026 | $3.05 | $3.57 | +17.0% |
| Feb 2026 | $1.63 | $1.99 | +22.1% |
| Oct 2025 | $3.88 | $4.81 | +24.0% |
| Jul 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Jul 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Jan 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Jan 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Jan 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $5.81 | — | — | $2.68B | — | — | — |
| Sep 2028 | $5.40 | — | — | $2.70B | — | — | — |
| Jun 2028 | $5.96 | — | — | $2.84B | — | — | — |
| Mar 2028 | $5.86 | — | — | $2.75B | — | — | — |
| Dec 2027 | $4.48 | — | — | $2.66B | — | — | — |
| Sep 2027 | $4.27 | — | — | $2.67B | — | — | — |
| Jun 2027 | $4.31 | — | — | $2.69B | — | — | — |
| Mar 2027 | $3.69 | — | — | $2.51B | — | — | — |
| Dec 2026 | $3.27 | — | — | $2.60B | — | — | — |
| Oct 28, 2026 | $2.03 | — | — | $2.64B | — | — | — |
| Jul 29, 2026 | $2.94 | $3.60 | +22.4% | $2.46B | $2.74B | +11.2% | +1.8% |
| Apr 29, 2026 | $3.05 | $3.57 | +17.0% | $2.29B | $2.48B | +8.4% | +6.0% |
| Feb 6, 2026 | $1.63 | $1.99 | +22.1% | $2.20B | $2.28B | +3.5% | +8.5% |
| Oct 30, 2025 | $3.88 | $4.81 | +24.0% | $2.34B | $2.45B | +4.9% | +1.2% |
| Jul 31, 2025 | |||||||
| May 1, 2025 | |||||||
| Feb 12, 2025 | |||||||
| Oct 30, 2024 | |||||||
| Aug 1, 2024 | |||||||
| Apr 24, 2024 | |||||||
| Feb 13, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Jul 25, 2023 | |||||||
| Apr 25, 2023 | |||||||
| Feb 15, 2023 | |||||||
| Oct 25, 2022 | |||||||
| Jul 20, 2022 | |||||||
| May 3, 2022 | |||||||
| Feb 3, 2022 | |||||||
| Oct 20, 2021 | |||||||
| Jul 22, 2021 | |||||||
| Apr 22, 2021 | |||||||
| Feb 3, 2021 | |||||||
| Oct 21, 2020 | |||||||
| Jul 22, 2020 | |||||||
| Apr 22, 2020 | |||||||
| Jan 30, 2020 | |||||||
| Oct 22, 2019 | |||||||
| Jul 23, 2019 | |||||||
| Apr 24, 2019 | |||||||
| Jan 29, 2019 | |||||||
| Oct 23, 2018 | |||||||
| Jul 24, 2018 | |||||||
| Apr 24, 2018 | |||||||
| Jan 25, 2018 | |||||||
| Oct 24, 2017 | |||||||
| Jul 25, 2017 | |||||||
| Apr 25, 2017 | |||||||
| Jan 26, 2017 | |||||||
| Oct 26, 2016 | |||||||
| Jul 21, 2016 | |||||||
| Apr 21, 2016 | |||||||
| Jan 27, 2016 | |||||||
| Oct 21, 2015 | |||||||
| Jul 24, 2015 |